Licochalcone A
Licochalcone A exhibits potent antimalarial activity via and might be developed into a new antimalarial drug. Licochalcone A had anti-tumor activity in all cell lines tested and enhanced the effect of paclitaxel and vinblastine chemotherapy. Licochalcone A induced apoptosis in MCF-7 and HL-60 cell lines, as demonstrated by cleavage of PARP, the substrate of ICE-like proteases. Licochalcone A exhibits a strong antileishmanial activity , that appropriate substituted chalcones might be a new class of antileishmanial drugs. (In Vitro) :Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC50 and Ki values lower than 5 μM) .
Product Specifications
CAS Number
58749-22-7
Product Name Alternative
Licochalcone A | Licochalcone-A
Purity
>98% (HPLC)
Solubility
Soluble in DMSO, Chloroform
Smiles
O=C (C1=CC=C (O) C=C1) /C=C/C2=CC (C (C) (C) C=C) =C (O) C=C2OC
Molecular Formula
C21H22O4
Molecular Weight
338.4
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
(E) -3- (4-hydroxy-2-methoxy-5- (2-methylbut-3-en-2-yl) phenyl) -1- (4-hydroxyphenyl) prop-2-en-1-one
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Anti-MERS-CoV (NCoV/Novel coronavirus) Spike Protein S2 Polyclonal Antibody
Anti-MERS-CoV (NCoV/Novel coronavirus) Spike Protein S2 Polyclonal Antibody
Anti-MERS-CoV (NCoV/Novel coronavirus) Spike Protein S2 Polyclonal Antibody
